Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adebimpe Oyowe

Neurology Braselton, GA Medical Doctor

NPI 1942654181 CMS profile 7499849

1515 River Pl Ste 340, Braselton, GA 30517

Open in the dashboard

General payments

$5,679

232 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adebimpe Oyowe of Braselton, GA is reported in the CMS Open Payments database as having received $5,679 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,371 73
2024 General $1,406 77
2023 General $2,559 66
2022 General $252 12
2021 General $91 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adebimpe Oyowe
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Adebimpe Oyowe were reported at $1,371. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Adebimpe Oyowe Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $91 $438 $104–$2,547 $132
2022 $252 $442 $103–$2,388 $149
2023 $2,559 $464 $119–$2,312 $160
2024 $1,406 $468 $119–$2,323 $164
2025 $1,371 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LivaNova USA, Inc. $1,460 5 payments
  2. AbbVie, Inc. $1,006 86 payments
  3. Pfizer Inc. $439 26 payments
  4. UCB, Inc. $433 17 payments
  5. Neurocrine Biosciences, Inc. $191 7 payments
  6. Argenx US, Inc. $176 7 payments
  7. SK Life Science, Inc. $173 6 payments
  8. Biogen, Inc. $168 7 payments
  9. Lundbeck LLC $156 6 payments
  10. Eisai Inc. $137 5 payments
  11. Other $1,339 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,431 228 payments
  2. Travel and Lodging $1,247 4 payments
Products named General payments · program years 2021–2025
  1. VNS Therapy $1,460 5 payments
  2. UBRELVY $711 71 payments
  3. NURTEC ODT $439 26 payments
  4. QULIPTA $386 38 payments
  5. ZAVZPRET $247 15 payments
  6. Briviact $224 8 payments
  7. INGREZZA $191 7 payments
  8. Nayzilam $149 6 payments
  9. Leqembi $137 5 payments
  10. VYVGART Hytrulo $137 5 payments
  11. Other $2,327 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

4,186

Median for Neurology: 833

Drug cost

$891,682

Median for Neurology: $202,670

Branded share of claims

23.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 24 $358,582
Vumerity Diroximel Fumarate Brand 14 $120,495
Ubrelvy Ubrogepant Brand 51 $81,231
Botox Onabotulinumtoxina Brand 37 $50,265
Aimovig Autoinjector Erenumab-Aooe Brand 57 $43,651
Briviact Brivaracetam Brand 11 $29,555
Nurtec Odt Rimegepant Sulfate Brand 20 $27,695
Lamictal Lamotrigine Brand 29 $22,929
Qulipta Atogepant Brand 21 $22,767
Keppra Levetiracetam Brand 13 $22,732

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$103,595

Of which drugs: $34,294

Medicare patients

402

Average age 75

Services billed

7,938

246 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 35%
Depression 35%
Ischemic heart disease 32%
Diabetes 29%
Alzheimer's or dementia 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 13 7,200 $34,294

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $172
$172 51 —
NURTEC ODT
  • PFIZER INC. $157
$157 20 —
VYVGART Hytrulo
  • ARGENX US, INC. $110
$110 — —
Briviact
  • UCB, Inc. $104
$104 11 —
Nayzilam
  • UCB, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record